Background:Although complications associated with pazopanib, a multitarget tyrosine kinase inhibitor, are known, periosteal reaction as a side effect has never been reported.Observation:We present a case involving a male pediatric patient with desmoid tumors treated for 6 months with pazopanib who presented with pain and periosteal reaction in the ilium and scapula. Three months after termination of pazopanib therapy, the periosteal reaction in the scapula resolved and that in the ilium improved.Conclusion:Children receiving pazopanib presenting with focal pain should be examined for the periosteal reaction; this knowledge may facilitate correct diagnosis of symptoms as a drug-associated finding.
|Journal||Journal of Pediatric Hematology/Oncology|
|Publication status||Published - 2020 Nov 1|
- periosteal reaction
- side effect
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health